Download Free Medical Adjuvant Therapy For Breast Cancer PowerPoint Presentation

Adjuvant Therapy For Breast Cancer PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Breast Cancer (Inflammatory), which is titled "Adjuvant Therapy For Breast Cancer", to know about breast cancer as the most frequently diagnosed cancer and adjuvant therapy.

Tags : Breast Cancer, Inflammatory, Systemic Therapy, Adjuvant

Published on : May 10, 2021 | Views : 1861 | Downloads : 11

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Adjuvant Therapy For Breast Cancer
Slide 2-

Breast Cancer | Epidemiology- Australia Australian Institute of Health and Welfare 2014. ACIM (Australian Cancer Incidence and Mortality) Books. Canberra. AIHW Overall is the third leading cause of cancer Most common cause of cancer in women
Slide 3-

Incidence rates higher in economically developed regions Inc. Australia, Western Europe, Nth. America Increased Incidence in 1980-1990 increased screening Decline in incidence in since 2000 HRT related Worldwide increase in incidence Developing Countries Breast Cancer | Worldwide Incidence
Slide 4-

Breast Cancer | Established Risk Factors: FIXED
Slide 5-

Breast Cancer | Established Risk Factor: MODIFIABLE
Slide 6-

All breast cancer patients need consideration of adjuvant therapy There are multiple possible treatment options which can be used individually or combined Includes not only chemotherapy but endocrine and targeted therapy Who to treat with which agents…. Prognostic factors Predictive factors Breast Cancer | Who needs Adjuvant Therapy?
Slide 7-

Patient Age Performance Status Breast Cancer | The patient in front of you
Slide 8-

Breast Cancer | Staging: AJCC Tumour Staging
Slide 9-

Breast Cancer | Staging: AJCC TNM Staging AJCC Cancer Staging Manual, 7th Edition (2010) Springer Science and Business Media LLC
Slide 10-

Both prognostic and predicative information Breast Cancer | Intrinsic Molecular Subtypes Synder R. Update of breast cancer FRACP Pt1. (2013)
Slide 11-

Gene expression profiling Assessment of the risk of both local and systemic recurrence among breast cancers with a more FAVOURABLE profile Those with low risk are unlikely to significantly benefit from CTx Oncotype DX ( 21 genes) Breast Cancer | Gene Expression Signatures Va de Vijver et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. NEJM. 2002: 347: 1999-2009 Paik et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. NEJM: 2004: 351: 2817-2826
Slide 12-

Breast Cancer | Oncotype
Slide 13-

Breast Cancer | Oncotype
Slide 14-

Breast Cancer | TAILORx Trial
Slide 15-

Breast Cancer | Anatomical LN Involvement Without Systemic Treatment 1-3 LN: 25-35% recurrence rate 4-9 LN: 25-55% recurrence rate >10 LN: >70% recurrence rate Quiet et al. Natural History of node positive breast cancer: the curability of small cancers with a limited number of positive nodes. J Clin Oncol. 1996; 14:3105-3111
Slide 16-

Breast Cancer | Histology Histological Classification Ductal (75%) Lobular (10%) Tubular (1-4%) Mucinous Medullary Papillary Micropapillary
Slide 17-

Breast Cancer | Stage I and II Local Disease Control Surgery Breast Conservation Surgery Mastectomy With sentinel lymph node biopsy in both Radiation Whole Breast Radiotherapy Applied to the tumour bed, over a course of 5-6 week, or in older patients this can be shortened to a 2-3 week period Majority of local tumour recurrences occur at or around the tumour bed or localised lymph nodes
Slide 18-

Things taken into account when planning adjuvant therapy Age ECOG Tumour size Tumour Histology Lymphatic Invasion Proliferative Rate Hormone Receptor Status HER2 Status Intrinsic Molecular Subtypes Gene Expression Signatures Patient Preference Breast Cancer | Therefore….
Slide 19-

Breast Cancer | Chemotherapy
Slide 20-

Breast Cancer | Historical Chemotherapy Timeline Verrill M, Chemotherapy for early-stage breast cancer: a brief history. British Journal of Cancer (2009)
Slide 21-

CMF (Cyclophosphamide, Methotrexate, 5-FU) AC (Doxorubicin, Cyclophosphamide) FEC (5-FU, Epirubicin, Cyclophosphamide) AC-docetaxel, AC-paclitaxel Dose Dense AC FEC-T Breast Cancer | Historical Chemotherapy Timeline
Slide 22-

Breast Cancer | What is Gold Standard? Peto, R San Antonia Breast Cancer Symposium on behalf of the Early Breast Cancer Trialists’ Collaborative Group
Slide 23-

EBCTCG meta-analysis (2011) Anthracycline- containing regimens Decreased risk of recurrence resulting in an absolute reduction of 8% Reduction of BC mortality to an absolute decreased of 6.5% Reduction in overall mortality to an absolute of 5.0% CMF Decrease in the risk of recurrence in an absolute reduction of 10.2% Reduction in BC mortality to an absolute decreased of 6.2% Reduction in overall mortality to absolute decrease of 4.7% Breast Cancer | Rationale for Adjuvant Therapy
Slide 24-

Breast Cancer | Adjuvant CTx: General Principles Maintain full dose density Women > 70 need more individualised decisions There is no added benefit to dose escalation in adjuvant treatment Poly-chemotherapy is preferred
Slide 25-

Breast Cancer | High Grade Basal Disease Accounts for 10-15% of all breast cancer More common in young and/or black patients Commonly presents as higher grade Prognosis is more difficult Does not correlate as closely with tumour size or nodal involvement Requires treatment with adjuvant CTx at a smaller tumour size
Slide 26-

Hormone Receptors Oestrogen/ Progesterone Regulate gene expression through interaction with hormone response elements. Breast Cancer | Oestrogen and Progesterone Receptors
Slide 27-

Positive prognostic indicator Late disease recurrence ER/PR –ve: greatest risk < 5 years, then dramatic decline ER/PR +ve: Slower rise in recurrence and more gradual decline Predictive indicator Of response to endocrine therapy Higher degrees of positivity indicate increased response Breast Cancer | Oestrogen and Progesterone Receptors
Slide 28-

Endocrine Therapy Reduces the risk of systemic recurrence Increased overall survival All women regardless of age, menopausal status, nodal involvement, tumour size, HER2 status or use of chemotherapy Therefore almost universal use across the population of HR +ve patients Breast Cancer | Hormone Receptor +ve disease
Slide 29-

The diagnosis of menopause is made at the time of diagnosis Tamoxifen for 5 years is the current standard therapy Aromatase Inhibitors are not active for women with intact ovarian function Including amenorrhic women secondary to chemotherapy Ovarian Suppression Ovarian ablation/ Oophorectomy LHRH agonist Breast Cancer | Endocrine Therapy: Pre-menopausal
Slide 30-

Breast Cancer | Endocrine Therapy: Tamoxifen
Slide 31-

Breast Cancer | Aromatase Inhibitors Suppress plasma oestrogen levels by inhibiting or inactivating aromatase
Slide 32-

Anastrozole Letrozole Exemestane (steroidal inhibitor) Comparable in efficacy Similar SE profile Arthralgias, myalgias, reduction in bone density Breast Cancer | Postmenopausal HR+ve
Slide 33-

Breast Cancer | Tamoxifen or AI
Slide 34-

Breast Cancer | Tamoxifen then AI
Slide 35-

Breast Cancer | Big 1-98 trial
Slide 36-

Breast Cancer | Adjuvant Endocrine Therapy
Slide 37-

Member of the epidermal growth factor receptor tyrosine kinase family EGFR-1, HER2, HER3, HER4 Breast Cancer | HER-2
Slide 38-

Breast Cancer | HER2 Overamplification
Slide 39-

Overexpression of the HER2 protein is a consequence of gene amplification Occurs in 20% of BC Strong predictive indicator Increased efficacy of certain CTx agents Increased resistance to endocrine therapy Modest prognostic indicator Independent of other prognostic indicators Breast Cancer | HER2 Overamplification
Slide 40-

Trastuzumab (Herceptin) Adjuvant: survival advantage IV delivery ? Role for s/c in future Side effect profile Modify cardiac muscles response to stress 5% of patients experience asymptomatic decrease in EF Increased risk with advanced age, HTN, poor initial EF Breast Cancer | Trastuzumab
Slide 41-

Breast Cancer | Seminal Adjuvant Trastuzumab Trials
Slide 42-

HER2 is a tyrosine kinase receptor that activates downstream oncogenic signaling pathways HER2/HER3 Dimers may provide an escape mechanism for trastuzumab Therefore it has been postulated that a combination of HER2 receptor targets may have synergistic effects Breast Cancer | New Therapies
Slide 43-

Pertuzumab Shows survival benefit in neo-adjuvant and metastatic setting NCCN guidelines 2014 indicate that it can be incorporated into adjuvant treatment alongside CTx and trastuzumab Adjuvant trials ongoing Breast Cancer | Other HER2 receptor based therapy
Slide 44-

Breast Cancer | Other HER2 receptor based therapy
Slide 45-

Improvement in pCR with use of dual HER2 blocking therapy and CTx Increased efficacy in the patients with ER/PR –ve disease Breast Cancer | Neo-Sphere trial
Slide 46-

THANK YOU